Intuitive Surgical Soars: Revenue Up 23%, Net Income Jumps 25%

TL;DR

**ISRG is crushing it, buy the dip if you can find one; their robotic surgery dominance is only getting stronger.**

AI Summary

Intuitive Surgical, Inc. (ISRG) demonstrated robust financial performance for the three and nine months ended September 30, 2025. Total revenue for the three months increased by 23% to $2,505.1 million from $2,038.1 million in the prior year, driven by a 23.4% rise in product revenue to $2,109.2 million and a 20.4% increase in service revenue to $395.9 million. Net income attributable to Intuitive Surgical, Inc. for the three months surged by 24.6% to $704.4 million, up from $565.1 million in the same period of 2024. For the nine months, total revenue grew 21.2% to $7,198.5 million, and net income attributable to Intuitive Surgical, Inc. increased 25.9% to $2,061.2 million. The company's cash and cash equivalents significantly increased to $2,806.6 million as of September 30, 2025, from $2,027.4 million at December 31, 2024. Operating expenses rose, with selling, general, and administrative expenses at $573.3 million for the quarter and research and development at $329.4 million, reflecting continued investment in growth. Inventory also saw a substantial increase to $1,781.9 million from $1,487.2 million, indicating potential for future sales or supply chain adjustments. The company repurchased $2,094.3 million of common stock during the nine months ended September 30, 2025.

Why It Matters

This strong performance signals robust demand for Intuitive Surgical's da Vinci and Ion systems, reinforcing its dominant position in the robotic-assisted surgery market. For investors, the significant revenue and net income growth, coupled with a substantial increase in cash and a $2.09 billion share repurchase, indicates strong financial health and a commitment to shareholder returns, potentially driving further stock appreciation. Employees benefit from a growing company with continued investment in R&D, suggesting job stability and innovation opportunities. Customers, healthcare providers, gain access to advanced minimally invasive care, enhancing patient outcomes and operational efficiency. In a competitive landscape, ISRG's sustained growth widens its lead against emerging rivals, solidifying its market leadership.

Risk Assessment

Risk Level: medium — While financial performance is strong, the company faces 'uncertainties surrounding macroeconomic and geopolitical factors' including 'inflationary pressures, elevated interest rates, disruptions in commodity markets stemming from conflicts, such as those between Russia and Ukraine and conflicts in the Middle East, and supply chain challenges.' Additionally, 'recent tariff changes' are expected to 'increase the Company's cost of raw materials and finished goods imported from outside of the U.S.', which could impact future profitability despite current growth.

Analyst Insight

Investors should consider holding or initiating a position in ISRG, given the strong revenue and net income growth, coupled with significant cash generation and share repurchases. Monitor global macroeconomic and geopolitical developments, as well as tariff impacts, which could affect future costs and margins, but the current trajectory suggests continued market leadership.

Financial Highlights

debt To Equity

N/A

revenue

$2,505.1M

operating Margin

30.3%

total Assets

$19,351.8M

total Debt

N/A

net Income

$704.4M

eps

$1.95

gross Margin

66.4%

cash Position

$2,806.6M

revenue Growth

+23.0%

Revenue Breakdown

Key Numbers

• $2,505.1M — Total Revenue (3 months) (Up 23% from $2,038.1M in Q3 2024)
• $704.4M — Net Income (3 months) (Up 24.6% from $565.1M in Q3 2024)
• $7,198.5M — Total Revenue (9 months) (Up 21.2% from $5,938.6M in 9M 2024)
• $2,061.2M — Net Income (9 months) (Up 25.9% from $1,636.9M in 9M 2024)
• $2,806.6M — Cash and Cash Equivalents (Increased from $2,027.4M at Dec 31, 2024)
• $2,094.3M — Common Stock Repurchase (Executed during the nine months ended September 30, 2025)
• $1,781.9M — Inventory (Increased from $1,487.2M at Dec 31, 2024)
• $1.95 — Diluted EPS (3 months) (Up from $1.56 in Q3 2024)
• $5.67 — Diluted EPS (9 months) (Up from $4.53 in 9M 2024)

Key Players & Entities

• Intuitive Surgical, Inc. (company) — Registrant and primary entity in the filing
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (company) — Joint Venture partner
• FASB (regulator) — Financial Accounting Standards Board
• $2,505.1 million (dollar_amount) — Total revenue for the three months ended September 30, 2025
• $704.4 million (dollar_amount) — Net income attributable to Intuitive Surgical, Inc. for the three months ended September 30, 2025
• $2,061.2 million (dollar_amount) — Net income attributable to Intuitive Surgical, Inc. for the nine months ended September 30, 2025
• $2,806.6 million (dollar_amount) — Cash and cash equivalents as of September 30, 2025
• $2,094.3 million (dollar_amount) — Repurchase of common stock for the nine months ended September 30, 2025
• da Vinci surgical systems (company) — Key product line
• Ion endoluminal system (company) — Key product line

FAQ

Risk Factors

• Regulatory Scrutiny and Compliance [high — regulatory]: The company operates in a highly regulated industry, subject to extensive oversight from bodies like the FDA. Changes in regulations, delays in product approvals, or adverse findings in inspections could significantly impact operations and market access. For instance, ongoing post-market surveillance and potential recalls pose continuous risks.
• Competition and Technological Advancements [high — market]: The surgical robotics market is becoming increasingly competitive with new entrants and established medical device companies developing competing technologies. Failure to innovate and maintain a technological edge could lead to market share erosion. The company faces pressure to continuously improve its da Vinci system and develop next-generation platforms.
• Supply Chain Disruptions [medium — operational]: The significant increase in inventory to $1,781.9 million from $1,487.2 million suggests potential supply chain management efforts or anticipation of demand. However, disruptions in the global supply chain for critical components could impact manufacturing capacity and product availability, affecting revenue realization.
• Foreign Currency Exchange Rate Fluctuations [medium — financial]: A substantial portion of revenue is generated internationally. Fluctuations in foreign currency exchange rates can adversely affect reported revenues, expenses, and profitability when translated into U.S. dollars. The company's hedging strategies may not fully mitigate this risk.
• Product Liability and Litigation [medium — legal]: The use of complex medical devices carries inherent risks of product liability claims and potential litigation. Adverse outcomes in such legal proceedings could result in significant financial liabilities and reputational damage.
• Dependence on Key Personnel and Talent Acquisition [low — operational]: The company's success relies on its ability to attract, retain, and motivate highly skilled personnel, particularly in engineering, research and development, and sales. Competition for talent in the medical technology sector is intense.

Industry Context

Intuitive Surgical operates in the rapidly evolving medical technology sector, specifically robotic-assisted surgery. The industry is characterized by high R&D investment, stringent regulatory oversight, and increasing competition from both established players and innovative startups. Key trends include expanding minimally invasive procedures, advancements in AI and data analytics for surgical insights, and a growing global adoption of robotic platforms.

Regulatory Implications

The company faces significant regulatory hurdles, primarily from the FDA in the U.S. and similar bodies internationally. Compliance with evolving regulations, successful navigation of approval processes for new products and indications, and adherence to manufacturing standards are critical. Any regulatory setbacks, such as product recalls or warning letters, could materially impact operations and market reputation.

What Investors Should Do

1. Monitor competitive landscape
2. Analyze inventory growth
3. Evaluate R&D and SG&A spending
4. Assess cash deployment strategy

Key Dates

• 2025-09-30: End of Q3 2025 — Reported strong revenue growth of 23% and net income increase of 24.6%, demonstrating continued market demand and operational efficiency.
• 2025-09-30: Balance Sheet Date — Showcased a robust cash position of $2,806.6 million, up from $2,027.4 million at year-end 2024, indicating strong cash generation.
• 2025-09-30: Nine Months Ended — Achieved significant year-to-date revenue growth of 21.2% and net income growth of 25.9%, alongside substantial common stock repurchases totaling $2,094.3 million.

Glossary

Product Revenue

Revenue generated from the sale of surgical systems, instruments, and accessories. (A primary driver of ISRG's top-line growth, indicating demand for their core robotic surgery technology.)

Service Revenue

Revenue derived from servicing, maintenance, training, and other support services for installed systems. (Represents a recurring revenue stream that complements product sales and contributes to overall profitability.)

Retained Earnings

The cumulative net income of a company that has not been distributed to shareholders as dividends. (Shows the company's historical profitability and its ability to reinvest earnings back into the business.)

Accumulated other comprehensive income (loss)

Unrealized gains or losses that bypass the income statement but affect equity, such as foreign currency translation adjustments. (Provides insight into potential unrealized gains/losses impacting equity, with a negative balance in the prior year suggesting foreign currency headwinds.)

Noncontrolling interest in joint venture

The portion of equity in a subsidiary that is not attributable to the parent company, arising from joint ventures. (Indicates the company's involvement in and share of profits/losses from specific joint ventures.)

Diluted EPS

Earnings per share calculated after accounting for all dilutive potential common shares, such as stock options and convertible securities. (A key profitability metric for shareholders, reflecting the earnings generated per share of common stock outstanding.)

Year-Over-Year Comparison

Compared to the prior year's comparable periods, Intuitive Surgical has demonstrated impressive growth. Total revenue for the three months ended September 30, 2025, increased by 23.0% to $2,505.1 million, outpacing the prior year's growth. Net income also saw a substantial rise of 24.6% to $704.4 million. Operating expenses, including SG&A and R&D, have increased, reflecting continued investment. The balance sheet shows a stronger cash position and a notable increase in inventory, suggesting proactive inventory management or anticipation of demand.

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select

Filing Documents

• isrg-20250930.htm (10-Q) — 1821KB
• q325ex-311xceocertofsoxsec.htm (EX-31.1) — 11KB
• q325ex-312xcfocertofsoxsec.htm (EX-31.2) — 11KB
• q325ex-321xceocertofsoxsec.htm (EX-32.1) — 5KB
• q325ex-322xcfocertofsoxsec.htm (EX-32.2) — 5KB
• 0001035267-25-000209.txt ( ) — 10081KB
• isrg-20250930.xsd (EX-101.SCH) — 50KB
• isrg-20250930_cal.xml (EX-101.CAL) — 95KB
• isrg-20250930_def.xml (EX-101.DEF) — 254KB
• isrg-20250930_lab.xml (EX-101.LAB) — 699KB
• isrg-20250930_pre.xml (EX-101.PRE) — 484KB
• isrg-20250930_htm.xml (XML) — 2110KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (unaudited)

Financial Statements (unaudited): Condensed Consolidated Balance Sheets as of September 30, 2025 , and December 31, 2024 3 Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 30, 2025 , and 2024 4 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 , and 2024 5 Notes to C ondensed C onsolidated F inancial S tatements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 51 Item 4.

Controls and Procedures

Controls and Procedures 51

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 52 Item 1A.

Risk Factors

Risk Factors 52 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52 Item 3. Defaults Upon Senior Securities 52 Item 4. Mine Safety Disclosures 52 Item 5. Other Information 52 Item 6. Exhibits 53 Signature 54 2

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS INTUITIVE SURGICAL, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) in millions (except par values) September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 2,806.6 $ 2,027.4 Short-term investments 2,102.2 1,985.9 Accounts receivable, net 1,259.7 1,225.4 Inventory 1,781.9 1,487.2 Prepaids and other current assets 574.9 385.1 Total current assets 8,525.3 7,111.0 Property, plant, and equipment, net 5,150.9 4,646.6 Long-term investments 3,523.7 4,819.1 Deferred tax assets 978.9 1,045.1 Intangible and other assets, net 824.9 773.9 Goodwill 348.1 347.5 Total assets $ 19,351.8 $ 18,743.2 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 291.2 $ 193.4 Accrued compensation and employee benefits 455.5 535.6 Deferred revenue 491.1 468.8 Other accrued liabilities 565.4 547.5 Total current liabilities 1,803.2 1,745.3 Other long-term liabilities 506.5 468.3 Total liabilities 2,309.7 2,213.6 Contingencies (Note 8) Stockholders' equity: Preferred stock, 2.5 shares authorized, $ 0.001 par value, issuable in series; zero shares issued and outstanding as of September 30, 2025, and December 31, 2024 — — Common stock, 600.0 shares authorized, $ 0.001 par value, 354.9 shares and 356.6 shares issued and outstanding as of September 30, 2025, and December 31, 2024, respectively 0.4 0.4 Additional paid-in capital 10,478.8 9,681.3 Retained earnings 6,424.0 6,803.3 Accumulated other comprehensive income (loss) 26.5 ( 51.3 ) Total Intuitive Surgical, Inc. stockholders' equity 16,929.7 16,433.7 Noncontrolling interest in joint venture 112.4 95.9 Total stockholders' equity 17,042.1 16,529.6 Total liabilities and stockholders' equity $ 19,351.8 $ 18,743.2 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited). 3 INTUITIVE SURGICAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)

View Full Filing

View this 10-Q filing on SEC EDGAR